HEALTHBiotech Premarket Movers: Spectrum, BioCryst, CurisBy Armie Margaret LeeMar 9, 2017 10:07 AM EST
PRESS RELEASESCuris® And DarwinHealth Announce Scientific Collaboration To Characterize Biomarkers And Tumor Subtype Alignments For Fimepinostat In DLBCL And Solid MalignanciesBy PR NewswireJan 13, 2020 8:00 AM EST
PRESS RELEASESCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)By PR NewswireJan 8, 2020 11:31 AM EST
PRESS RELEASESCuris Announces Option And License Agreement With ImmuNext For The Development And Commercialization Of Anti-VISTA AntibodiesBy PR NewswireJan 7, 2020 8:05 AM EST
PRESS RELEASESCuris Provides First-Ever Demonstration That Targeting IRAK4 In Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Results In Anti-Cancer Activity In Ongoing Phase 1 StudyBy PR NewswireDec 6, 2019 7:26 AM EST
PRESS RELEASESCuris Announces Positive Safety, Tolerability And Pharmacokinetic Data In Ongoing Phase 1 Study Of Fimepinostat In Combination With VenetoclaxBy PR NewswireDec 6, 2019 7:00 AM EST
HEALTHBiotech Premarket Movers: Spectrum, BioCryst, CurisBy Armie Margaret LeeMar 9, 2017 10:07 AM EST
STOCKSThese 7 stocks under $10 are making big moves higher. Here's how to trade them now.By Roberto PedoneAug 24, 2016 7:08 AM EDT
STOCKSBiotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbentsBy Adam FeuersteinOct 17, 2014 7:05 AM EDT
